JPWO2020043878A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020043878A5
JPWO2020043878A5 JP2021509758A JP2021509758A JPWO2020043878A5 JP WO2020043878 A5 JPWO2020043878 A5 JP WO2020043878A5 JP 2021509758 A JP2021509758 A JP 2021509758A JP 2021509758 A JP2021509758 A JP 2021509758A JP WO2020043878 A5 JPWO2020043878 A5 JP WO2020043878A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
alkyl
group
composition according
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535110A5 (https=
JP2021535110A (ja
JP7590083B2 (ja
Publication date
Priority claimed from GBGB1814207.5A external-priority patent/GB201814207D0/en
Priority claimed from GBGB1908225.4A external-priority patent/GB201908225D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/073212 external-priority patent/WO2020043878A1/en
Publication of JP2021535110A publication Critical patent/JP2021535110A/ja
Publication of JP2021535110A5 publication Critical patent/JP2021535110A5/ja
Publication of JPWO2020043878A5 publication Critical patent/JPWO2020043878A5/ja
Application granted granted Critical
Publication of JP7590083B2 publication Critical patent/JP7590083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509758A 2018-08-31 2019-08-30 併用療法 Active JP7590083B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1814207.5A GB201814207D0 (en) 2018-08-31 2018-08-31 Combination Therapy
GB1814207.5 2018-08-31
GBGB1908225.4A GB201908225D0 (en) 2019-06-10 2019-06-10 Combination therapy
GB1908225.4 2019-06-10
PCT/EP2019/073212 WO2020043878A1 (en) 2018-08-31 2019-08-30 Combination therapy

Publications (4)

Publication Number Publication Date
JP2021535110A JP2021535110A (ja) 2021-12-16
JP2021535110A5 JP2021535110A5 (https=) 2022-08-29
JPWO2020043878A5 true JPWO2020043878A5 (https=) 2022-08-29
JP7590083B2 JP7590083B2 (ja) 2024-11-26

Family

ID=67841060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509758A Active JP7590083B2 (ja) 2018-08-31 2019-08-30 併用療法

Country Status (16)

Country Link
US (1) US20210322564A1 (https=)
EP (1) EP3843748B1 (https=)
JP (1) JP7590083B2 (https=)
KR (1) KR20210054520A (https=)
CN (1) CN112638392B (https=)
AU (1) AU2019332979B2 (https=)
BR (1) BR112021003675A2 (https=)
CA (1) CA3107085A1 (https=)
ES (1) ES3037206T3 (https=)
IL (1) IL280968B2 (https=)
MX (1) MX2021001908A (https=)
PH (1) PH12021550376A1 (https=)
SG (1) SG11202101518QA (https=)
UA (1) UA128954C2 (https=)
WO (1) WO2020043878A1 (https=)
ZA (1) ZA202100467B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7740994B2 (ja) * 2019-06-10 2025-09-17 アーデーセー セラピューティクス ソシエテ アノニム 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2023274974A1 (en) * 2021-06-29 2023-01-05 Adc Therapeutics Sa Combination therapy using antibody-drug conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
DK2906298T3 (en) * 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
CN110869765A (zh) * 2017-04-20 2020-03-06 Adc治疗有限公司 组合疗法
MX2019015042A (es) * 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.

Similar Documents

Publication Publication Date Title
JP2018502902A5 (https=)
JP2019518741A5 (https=)
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2009536620A5 (https=)
JP2022020003A5 (https=)
CN114174303B (zh) 作为sting激动剂的大环化合物及其方法和用途
SI2809657T1 (en) New therapeutic agents
JP2008535902A5 (https=)
RU2007134396A (ru) Химические соединения
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2008535903A5 (https=)
JP2018524347A5 (https=)
CN108430993A (zh) Tank-结合激酶抑制剂化合物
FI4234581T3 (fi) Terapeuttisia vasta-aineita ja niiden käyttöjä
JP2017528467A5 (https=)
JP2016508130A5 (https=)
JP2014528467A5 (https=)
JP2012507566A5 (https=)
JP2020505433A5 (https=)
JP2021524449A5 (https=)
JP2009542610A5 (https=)
RU2019138222A (ru) Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
JP2020531414A5 (https=)
JP2012528099A (ja) Plk1阻害剤および抗腫瘍剤を含む治療組合せ
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물